Results 51 to 60 of about 8,824 (214)

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Telomere length in paroxysmal nocturnal hemoglobinuria correlates with clone size

, 2007
OBJECTIVE: To study if telomere length can be used as a surrogate marker for the mitotic history in normal and affected hematopoietic cells from patients with paroxysmal nocturnal hemoglobinuria (PNH).
Young, Neal S, Lansdorp, Peter M, Baerlocher, Gabriela M, Sloand, Elaine M   +3 more
core   +1 more source

From the Proteome to Therapeutics: A Multi‐Database Approach to Drug Discovery in Periodontitis—An Exploratory Pilot Study

Journal of Clinical Periodontology, Volume 53, Issue 7, Page 990-1004, July 2026.
ABSTRACT Introduction This explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug‐target database screening. Methods Proteomic analyses of saliva using LC–MS/MS were conducted in two independent settings: a cohort (sub‐study I, N = 187) and
Taisir Bozo, Annette Murr, Birte Holtfreter, Sebastian‐Edgar Baumeister, Peter Meisel, Uwe Völker, Werner Weitschies, Henry Völzke, Philipp Kanzow, Elke Hammer, Manuela Gesell Salazar, Thomas Kocher   +11 more
wiley   +1 more source

The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells

Haematologica, 2012
Background Patients with paroxysmal nocturnal hemoglobinuria harbor clonal glycosylphosphatidylinositol-anchor deficient cells arising from a multipotent hematopoietic stem cell acquiring a PIG-A mutation.
Jeffrey J. Pu, Rong Hu, Galina L. Mukhina, Hetty E. Carraway, Michael A. McDevitt, Robert A. Brodsky   +5 more
doaj   +1 more source

Paroxysmal nocturnal hemoglobinuria: Pandora’s box?

Journal of Mind and Medical Sciences, 2020
Introduction. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired non-malignant hematological disorder which affects the pluripotent hematopoietic stem cell.
Mihnea-Alexandru Găman, Iulia Ursuleac, Daniel Coriu   +2 more
doaj   +1 more source

Early‐Onset Mucocutaneous Findings and Isolated Progressive Thrombocytopenia in a Child With a DKC1 A353V Variant

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Dyskeratosis congenita (DC) is a rare telomere biology disorder characterized by mucocutaneous abnormalities and progressive bone marrow failure. We report a 10‐year‐old boy with a hemizygous DKC1 c.1058C > T (p.Ala353Val) variant who presented with unusually early mucocutaneous findings, including oral leukoplakia at 2 years of age, followed ...
Harun Kasapoğlu, Aslı Turgutoğlu Yılmaz, Berkin Berk Akbeyaz, Neslihan Çalışkan, Yılmaz Ay   +4 more
wiley   +1 more source

Off-Pump Coronary Revascularization Using Bilateral Internal Thoracic Arteries in A Patient with Paroxysmal Nocturnal Hemoglobinuria: A Case Report

Brazilian Journal of Cardiovascular Surgery
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-orphan disease. We report the first case in the literature of Off-Pump Coronary Revascularization Using Bilateral Internal Thoracic Arteries in a patient with paroxysmal nocturnal hemoglobinuria. A 36-
Juan Mariano Vrancic, Manuel Roque Cervetti, Julián Benavides, Daniel Navia   +3 more
doaj   +1 more source

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

Haematologica, 2010
Background Paroxysmal nocturnal hemoglobinuria is an acquired hemolytic anemia characterized by intravascular hemolysis which has been demonstrated to be effectively controlled with eculizumab.
Anita Hill, Russell P. Rother, Louise Arnold, Richard Kelly, Matthew J. Cullen, Stephen J. Richards, Peter Hillmen   +6 more
doaj   +1 more source

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source

Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia–Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation

Frontiers in Medicine, 2020
Pregnancies in paroxysmal nocturnal hemoglobinuria (PNH) are associated with increased morbidity and mortality. Retrospective studies suggest that outcome has improved with the advent of the complement inhibitor eculizumab.
Ferras Alashkar, Fuat H. Saner, Colin Vance, Ute Schmücker, Dörte Herich-Terhürne, Ulrich Dührsen, Angela Köninger, Alexander Röth   +7 more
doaj   +1 more source